Subscribe
Orlando, Fla. — Poorly controlled atopic dermatitis (AD) may remain elusive to treatment, particularly if its pathogenesis is not understood. While it is known that the altered barrier of atopic skin provides a portal of entry for various pathogens, it is the skin inflammation in AD that reduces the ability of patients with atopy to fight infection, according to Donald Y. M. Leung, M.D., Ph.D., head of pediatric allergy-immunology at the National Jewish Medical and Research Center in Denver.
Recognizing cosmetic photosensitivity, contact dermatitis
Latex allergy concerns spur steps to protect healthcare workers
Cortisol testing demonstrates systemic safety, efficacy for AD
Duo offers efficient, effective photon delivery
Joseph Gorelick, MSN, FNP-C
Brad P. Glick, DO, MPH, FAAD
Hilary Baldwin; Neal Bhatia, MD
Tina Bhutani, MD
June 17-19, 2026
Diego Ruiz Dasilva, MD, FAAD; Brad Glick, DO, MPH. FAAD; Peter Lio, MD
Brittany Weber MD, PhD, FACC, FAHA; Lourdes M. Perez-Chada MD, MMSc
Andrew Alexis, MD, MPH; Leon Kircik, MD
Johann Gudjonsson, MD, PhD; Christopher Bunick, MD, PhD
Andrew F. Alexis, MD, MPH; Chesahna Kindred, MD, MBA, FAAD